Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14779233 | 0.90 | CA1 (0.43) | CA1CA2CA9ALDH1A1CXCR2 | |
| SCHEMBL14780351 | 0.85 | CA1 (0.35) | CA1CA2CA9ALDH1A1CXCR2 | |
| SCHEMBL14779315 | 0.84 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL21178830 | 0.83 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL14779457 | 0.83 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL14780033 | 0.82 | CA1 (0.30) | CA1CA2CA9 | |
| SCHEMBL575704 | 0.79 | CA1 (0.33) | CA1CA2CA9ALDH1A1CXCR2 | |
| SCHEMBL778573 | 0.79 | ALDH1A1 (0.46) | CA1CA2CA9ALDH1A1CXCR2 | |
| SCHEMBL28139904 | 0.78 | CA1 (0.34) | CA1CA2CA9 | |
| SCHEMBL13047233 | 0.78 | ALDH1A1 (0.35) | CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125626-A1 | NITROGENOUS COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-06-20 | — | — | WO | disclosed |
| US-20220177446-A1 | ALKYNE COMPOUNDS AS IRAK INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. | 2022-06-09 | — | — | US | disclosed |
| WO-2019000237-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2863469-B1 | NONAQUEOUS ELECTROLYTE SECONDARY CELL AND METHOD FOR USING SAME | MITSUBISHI CHEM CORP (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-9240614-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| EP-2863469-A1 | NONAQUEOUS ELECTROLYTE SECONDARY CELL AND METHOD FOR USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2579377-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2579377-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071733-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177446-A1 | ALKYNE COMPOUNDS AS IRAK INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | IRAK2, IRAK3, IRAK4 | CA1 4798/4885CA2 4670/4885CA9 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.